Area of research
Cancer Research · Oncology · imunotherapy
Research interest
Research interests include Breast Cancer Treatment Studies, BRCA gene mutations in cancer, Advanced Breast Cancer Therapies, and HER2/EGFR in Cancer Research.
Assisted reproductive technology in young BRCA carriers with a pregnancy after breast cancer: An international cohort study
Breastfeeding after breast cancer in young <i>BRCA</i> carriers
Breastfeeding after breast cancer in young BRCA carriers.
Association between type and location of germline BRCA1/2 pathogenic or likely pathogenic variants with phenotype and prognosis in young patients with breast cancer: results from an international cohort study
Role of Radiotherapy in Elderly Patients (≥65 Years) With Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis.
Abstract GS01-10: HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-Positive Metastatic Breast Cancer
Galectin-3 secreted by triple-negative breast cancer cells regulates T cell function
The impact of germline BRCA pathogenic variants in locally advanced, triple negative breast cancer treated with platinum-based neoadjuvant chemotherapy
BRCA1/2 mutation carriers vs the general breast cancer population (N = 799,986): 21-gene assay-based molecular characterization.
Lasofoxifene versus fulvestrant for ER+/HER2− metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial
Pregnancy After Breast Cancer in Young <i>BRCA </i>Carriers
Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel
Clinical outcomes in estrogen receptor-positive early-stage breast cancer patients with Recurrence Score 26-30: observational real-world cohort study
Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial
MRI background parenchymal enhancement in patients with invasive lobular carcinoma: Endocrine hormonal treatment effect
Rate of breast biopsy referrals in female BRCA mutation carriers aged 50 years or more: a retrospective comparative study and matched analysis.
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer
Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer
Locoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysis
Efficacy and safety of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis
A novel role for an old target: CD45 for breast cancer immunotherapy.
The impact of endogenous estrogen exposures on the characteristics and outcomes of estrogen receptor positive, early breast cancer
Genetic testing in patients with triple-negative or hereditary breast cancer
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
Prospective Long-Term Follow-Up of Pulmonary Diffusion Capacity Reduction Caused by Dose-Dense Chemotherapy in Patients with Breast Cancer.
Talazoparib in Patients with Advanced Breast Cancer and a Germline <i>BRCA</i> Mutation
Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial